Document Detail


Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes.
MedLine Citation:
PMID:  7512175     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Activation of the N- and K-ras proto-oncogenes is the most common molecular abnormality in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In retrospective studies, approximately 3-36% of MDS patients were reported to harbor a mutated ras proto-oncogene, with some series suggesting the presence of ras-mutations are associated with progressive disease and a poor prognosis. Since hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) are currently used for therapy in MDS but may stimulate the proliferation of leukemic cells, we assessed the frequency and significance of ras mutations in 27 MDS patients, 15 of whom underwent G-CSF therapy. Patients were analyzed for the presence of mutations in codons 12, 13, and 61 of the N- and K-ras proto-oncogenes. Only three patients (11%, two refractory anemia with excess of blasts (RAEB), one RAEB in transformation (RAEB-T)) harbored activated ras oncogenes with the mutations localized in N-ras codons 12 and 61. Patients were followed for periods of up to 4 years or until death supervened. Patients exhibiting ras mutations were no more likely to develop AML compared to ras-negative patients (1/3 vs. 10/24) or to have decreased survival (p = 0.64). These data indicate that, in this group of MDS patients, ras mutations do not appear to correlate with a poor prognosis, and do not adversely interact with exogenously administered G-CSF.
Authors:
A Neubauer; P Greenberg; R Negrin; N Ginzton; E Liu
Related Documents :
6644705 - Acetylator phenotype and the effect of dapsone in rheumatoid arthritis.
17433865 - The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflamma...
17876645 - Associations between hla-drb1, rank, rankl, opg, and il-17 genotypes and disease severi...
10893295 - Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukem...
23076075 - Oxidative stress in alzheimer's disease and mild cognitive impairment with high sensiti...
7591335 - Prolonged therapy by the combination of furosemide and thiazides in refractory heart fa...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia     Volume:  8     ISSN:  0887-6924     ISO Abbreviation:  Leukemia     Publication Date:  1994 Apr 
Date Detail:
Created Date:  1994-05-10     Completed Date:  1994-05-10     Revised Date:  2013-03-04    
Medline Journal Info:
Nlm Unique ID:  8704895     Medline TA:  Leukemia     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  638-41     Citation Subset:  IM    
Affiliation:
Department of Medicine and Genetics, Lineberger Cancer Research Center, University of North Carolina at Chapel Hill.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Anemia, Refractory / genetics
Anemia, Refractory, with Excess of Blasts / genetics,  therapy
Codon / genetics
Genes, ras / genetics*
Granulocyte Colony-Stimulating Factor / therapeutic use
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
Humans
Leukemia, Myeloid / genetics,  therapy
Mutation / genetics*
Myelodysplastic Syndromes / genetics*,  therapy
Grant Support
ID/Acronym/Agency:
R01-CA36915/CA/NCI NIH HHS; R01-CA49240-01/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Codon; 143011-72-7/Granulocyte Colony-Stimulating Factor; 83869-56-1/Granulocyte-Macrophage Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes...
Next Document:  Epitope tagging of DAB389IL-2: new insights into C-domain delivery to the cytosol of target cells.